Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2026-02-25 @ 8:11 PM
Study NCT ID:
NCT02010567
Status:
TERMINATED
Last Update Posted:
2020-11-03
First Post:
2013-12-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
Sponsor:
UNC Lineberger Comprehensive Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Rectal Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | rectal cancer | View |
| None | colorectal cancer | View |
| None | locally advanced rectal cancer | View |
| None | locally advanced rectal cancer (resectable) | View |
| None | locally advanced rectal cancer (non-resectable) | View |
| None | chemoradiotherapy | View |
| None | nanopharmaceutical | View |
| None | CLRX101 | View |
| None | camptothecin | View |
| None | capecitabine | View |